- Details
- Axel Heidenreich discusses the final results of the COTRIMS trial, evaluating retroperitoneal lymph node dissection (RPLND) for clinical stage IIA and IIB seminomas. The study demonstrates high oncological efficacy with a 100% overall survival and 88% treatment-free survival after a median follow-up of three years. Dr. Heidenreich emphasizes the benefits of nerve-sparing RPLND, including preserved...
|
- Details
- Ruchika Talwar host Nirmish Singla to discuss a study on testicular cancer outcomes in Hispanic men. Dr. Singla presents findings from a SEER registry analysis spanning 20 years, revealing that Hispanic patients are more likely to be diagnosed at a younger age but with more aggressive disease characteristics. The study shows lower cancer-specific survival for Hispanics with non-seminoma across all...
|
- Details
- Zach Klaassen and Khalid Alkhatib discuss the significant cardiovascular risks faced by testicular cancer survivors. Dr. Alkhatib explains that the exact mechanisms behind this increased risk are not fully understood but are thought to be related to chemotherapy, particularly with Cisplatin, and associated conditions like metabolic syndrome and hypogonadism. Their study, utilizing a 15-year nation...
|
- Details
- Zach Klaassen discusses his lecture on the topic of testicular cancer and survivorship during a discussion with Alicia Morgans. Highlighting the long-term effects of chemotherapy, Dr. Klaassen emphasizes the profound impact on young patients who often live decades post-diagnosis. His presentation addresses the serious long-term toxicities, noting that one in five survivors experiences significant...
|
- Details
- Ruchika Talwar interviews Daniel Joyce about his journey into cost-effectiveness studies, particularly in testicular cancer. Initially skeptical, Dr. Joyce now sees these studies as crucial for interpreting clinical trial data in real-world contexts. He discusses his analysis of the SEMS trial, focusing on small-volume stage two seminoma, where RPLND emerged as the most cost-effective option compa...
|
- Details
- Zach Klaassen hosts a discussion with Connor O'Leary and Freeman McClusky, both testicular cancer survivors. They delve into the history and mission of Testicular Cancer Foundation (TCF), emphasizing its focus on education, awareness, and support since its inception in 2009. The conversation highlights the importance of community and brotherhood among survivors, with TCF playing a pivotal role in...
|
- Details
- Zach Klaassen interviews Lucia Nappi about her research on the role of microRNAs in early-stage testicular cancer. MicroRNAs are small RNA fragments crucial for the regulation of oncogenes and tumor suppressors, with certain microRNAs notably overexpressed in testicular cancer. Dr. Nappi's team analyzed the microRNA-371 in plasma samples from stage I testicular cancer patients, finding that patien...
|
- Details
- Philippe Spiess speaks about the Global Society of Rare GU Tumors. The society was founded by him and Andrea Necchi, who realized that rare cancers are underrepresented, particularly in clinical trials and peer-reviewed publications. The society's mission is to advance the care and management of rare GU tumors through global collaborations with the scientific community and patient advocacy. Biogra...
|
- Details
- Daniel Joyce joins Sam Chang to discuss oncologic outcomes, costs, and quality metrics for patients with both synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC). Upper tract urothelial carcinoma accounts for around 10% of all urothelial cancer cases that appear. Just around half of those will develop metastatic illness. This work's main objective was to determine what...
|
- Details
- Arya Roy joins Alicia Morgans to discuss her work on the role of neoadjuvant chemotherapy on the sarcomatoid variant of bladder cancer. This research earned Dr. Roy a 2023 ASCO GU Merit Award at this year's ASCO Genitourinary Cancers Symposium. Sarcomatoid bladder cancer is an extremely rare and aggressive histological variant with a poor prognosis and limited consensus regarding its management. D...
|
